Alliance Global downgraded Aptose Biosciences (APTOF) to Neutral from Buy with a C$2.41 price target The firm does not expect better offer than the Hanmi tender.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APTOF:
- Aptose Biosciences to be Acquired by Hanmi Pharmaceutical
- Aptose Biosciences Reports Financial Challenges in Q3 2025
- Aptose Biosciences Reports Promising Results in AML Therapy Trials
- Aptose Biosciences’ TUSCANY Study Highlighted at ASH 2025
- Aptose Biosciences’ Tuspetinib Study: A Potential Game-Changer in Leukemia Treatment